ClinicalTrials.gg
CompletedNCT02654054Updated Jun 29, 2020Results posted

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

A Phase 3 interventional study of Elagolix and Placebo for Estradiol/Norethindrone Acetate in Uterine Fibroids and Heavy Menstrual Bleeding, sponsored by AbbVie. Completed at 96 sites in 3 countries. Open to female participants aged 18 Years to 51 Years. Per ClinicalTrials.gov, last updated 2020-06-29.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
18 Years to 51 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Leiomyoma by AbbVie — none open to participants now, none under way, none of them phase 3. Leiomyoma · AbbVie.

Enrollment
5th of 28
413 · median 61
Started
2015
with 3 others
Phase 3
14 of 33
none open now
Registered
24th of 33
by date

Among the 33 studies in Leiomyoma by AbbVie, this one is the 5th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2015, is one of 14 in phase 3, and was the 24th registered.

Leiomyoma

438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

None of the 33 studies in Leiomyoma by AbbVie is open now. The open studies under Leiomyoma, anywhere →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 22 (50%) set no upper age limit and 21 (48%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 51 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Leiomyoma by AbbVie as a file.
02

Study summary

This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

03

Conditions studied

  • Uterine Fibroids
  • Heavy Menstrual Bleeding

Keywords

  • Elagolix
  • Elagolix Sodium
  • Heavy Uterine Bleeding
  • Heavy Menstrual Bleeding
  • Leiomyomata
  • Menorrhagia
  • ABT-620
  • Elagolix + E2/NETA
  • Elagolix + Norethindrone Acetate
  • HMB
04

Who can participate

Ages eligible
18 Years to 51 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a premenopausal female at the time of Screening.
  • Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound (transabdominal ultrasound/transvaginal ultrasound).
  • Subject has heavy menstrual bleeding associated with uterine fibroids as evidenced by menstrual blood loss > 80 mL during each of two screening menses as measured by the alkaline hematin method.
  • Subject has negative urine and/or serum pregnancy test in Screening and just prior to first dose.
  • Subject has an adequate endometrial performed during Screening, the results of which show no endometrial pathology.

Exclusion criteria

Exclusion Criteria:

  • Subject has screening pelvic ultrasound or saline infusion sonohysterography results that show a gynecological disorder.
  • Subject has history of osteoporosis or other metabolic bone disease.
  • Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis.
  • Subject has a history of major depression or post-traumatic stress disorder (PTSD) within 2 years of screening, OR a history of other major psychiatric disorder at any time (e.g., schizophrenia, bipolar disorder).
  • Subject is using any systemic for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the course of the study. Over the counter and prescription topical, inhaled, intranasal or injectable (for occasional use) corticosteroids are allowed.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
413 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/NETA) once daily (QD)

    Drug: Placebo for Estradiol/Norethindrone Acetate · Drug: Placebo for Elagolix

  • Experimental
    Elagolix

    Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD

    Drug: Elagolix · Drug: Placebo for Estradiol/Norethindrone Acetate

  • Experimental
    Elagolix + E2/NETA

    Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD

    Drug: Elagolix · Drug: Estradiol/Norethindrone Acetate

Interventions

  • Film-coated tablets

    Also known as: ABT-620, elagolix sodium

  • DrugPlacebo for Estradiol/Norethindrone Acetate

    Placebo capsules

  • DrugEstradiol/Norethindrone Acetate

    Drug pages: Estradiol · Norethindrone Acetate

    Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.

    Also known as: E2/NETA

  • DrugPlacebo for Elagolix

    Film-coated placebo tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Meeting the Criteria for Responder

    Percentage of responders, defined as participants who met the following conditions: * Menstrual blood loss (MBL) volume \< 80 mL during the Final Month (the last 28 days prior to and including the Reference Day, which is defined as the last visit date during the Treatment Period \[last treatment visit date\] or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date), and * ≥ 50% reduction in MBL volume from Baseline to the Final Month. Participants who prematurely discontinued study drug due to "lack of efficacy," "requires surgery or invasive intervention for treatment of uterine fibroids," or "adverse events" were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not.

    Time frame: Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

Secondary outcomes

  1. Change From Baseline in MBL Volume to the Final Month

    Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.

    Time frame: Month 0 (Baseline), Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

  2. Percentage of Participants With Suppression of Bleeding at the Final Month

    Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.

    Time frame: Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

  3. Change From Baseline in MBL Volume to Month 6

    Time frame: Month 0 (Baseline), Month 6

  4. Change From Baseline in MBL Volume to Month 3

    Time frame: Month 0 (Baseline), Month 3

  5. Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6

    Time frame: Month 0 (Baseline), Month 6

  6. Change From Baseline in MBL Volume to Month 1

    Time frame: Month 0 (Baseline), Month 1

07

Results

Posted Jun 29, 2020

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestonePlaceboElagolixElagolix + E2/NETA
Started102104207
Randomized and treated102104206
Completed8381164
Not completed192343
Post-Treatment Follow-Up Period
Participant flow — Post-Treatment Follow-Up Period
MilestonePlaceboElagolixElagolix + E2/NETA
Started253259
Completed172429
Not completed8830
Withdrew: Withdrawal by subject267
Withdrew: Lost to follow-up3013
Withdrew: Required surgery/invasive intervention222
Withdrew: Other104
Withdrew: Non-compliance004

Outcome measures

PrimaryPercentage of Participants Meeting the Criteria for Responder

Percentage of responders, defined as participants who met the following conditions: * Menstrual blood loss (MBL) volume \< 80 mL during the Final Month (the last 28 days prior to and including the Reference Day, which is defined as the last visit date during the Treatment Period \[last treatment visit date\] or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date), and * ≥ 50% reduction in MBL volume from Baseline to the Final Month. Participants who prematurely discontinued study drug due to "lack of efficacy," "requires surgery or invasive intervention for treatment of uterine fibroids," or "adverse events" were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not.

Time frame:
Final Month (the last 28 days prior to and including the Reference Day), up to Month 6
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Criteria for Responder
percentage of participantsPlaceboElagolixElagolix + E2/NETA
Percentage of Participants Meeting the Criteria for Responder8.784.168.5
Statistical analysis
  • Placebo vs Elagolix · Regression, Logistic · p = < 0.001 (The P value for test of difference is by pooling the results from a logistic regression model including treatment as the main effect and baseline MBL volume as a covariate in each data set from multiple imputation.) · Odds ratio (or): 56.79 · 95% CI 23.002 to 140.227
  • Placebo vs Elagolix + E2/NETA · Regression, Logistic · p = < 0.001 (The P value for test of difference is by pooling the results from a logistic regression model including treatment as the main effect and baseline MBL volume as a covariate in each data set from multiple imputation.) · Odds ratio (or): 22.98 · 95% CI 10.466 to 50.451
SecondaryChange From Baseline in MBL Volume to the Final Month

Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.

Time frame:
Month 0 (Baseline), Final Month (the last 28 days prior to and including the Reference Day), up to Month 6
Reported as:
Least squares mean · mL
Change From Baseline in MBL Volume to the Final Month
mLPlaceboElagolixElagolix + E2/NETA
Change From Baseline in MBL Volume to the Final Month0.8 ± 14.86-221.5 ± 14.49-176.7 ± 10.40
Statistical analysis
  • Placebo vs Elagolix · ANCOVA · p = < 0.001 (The P value for test of difference between each elagolix treatment group and placebo is by pooling the results from an ANCOVA model with treatment as the main effect and baseline MBL volume as a covariate in each dataset from multiple imputation.) · Ls mean of difference: -222.3
  • Placebo vs Elagolix + E2/NETA · ANCOVA · p = < 0.001 (The P value for test of difference between each elagolix treatment group and placebo is by pooling the results from an ANCOVA model with treatment as the main effect and baseline MBL volume as a covariate in each dataset from multiple imputation.) · Ls mean of difference: -177.5
SecondaryPercentage of Participants With Suppression of Bleeding at the Final Month

Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.

Time frame:
Final Month (the last 28 days prior to and including the Reference Day), up to Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With Suppression of Bleeding at the Final Month
percentage of participantsPlaceboElagolixElagolix + E2/NETA
Percentage of Participants With Suppression of Bleeding at the Final Month4.484.056.8
Statistical analysis
  • Placebo vs Elagolix · Chi-square or Fisher's exact test · p = < 0.001 (The P value is calculated based on chi-square test (or Fisher's exact test if ≥ 20% of the cells have expected cell count \< 5).) · Between-group difference (%): 79.6 · 95% CI 71.13 to 88.16
  • Placebo vs Elagolix + E2/NETA · Chi-square or Fisher's exact test · p = < 0.001 (The P value is calculated based on chi-square test (or Fisher's exact test if ≥ 20% of the cells have expected cell count \< 5).) · Between-group difference (%): 52.4 · 95% CI 44.11 to 60.76
SecondaryChange From Baseline in MBL Volume to Month 6
Time frame:
Month 0 (Baseline), Month 6
Reported as:
Least squares mean · mL
Change From Baseline in MBL Volume to Month 6
mLPlaceboElagolixElagolix + E2/NETA
Change From Baseline in MBL Volume to Month 6-2.3 ± 13.53-236.2 ± 13.74-194.7 ± 9.77
Statistical analysis
  • Placebo vs Elagolix · mixed model repeated measures · p = < 0.001 (The P value is from mixed models repeated measures (MMRM) with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -234.0
  • Placebo vs Elagolix + E2/NETA · mixed model repeated measures · p = < 0.001 (The P value is from mixed models repeated measures (MMRM) with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -192.5
SecondaryChange From Baseline in MBL Volume to Month 3
Time frame:
Month 0 (Baseline), Month 3
Reported as:
Least squares mean · mL
Change From Baseline in MBL Volume to Month 3
mLPlaceboElagolixElagolix + E2/NETA
Change From Baseline in MBL Volume to Month 36.1 ± 15.32-234.7 ± 15.38-192.2 ± 10.81
Statistical analysis
  • Placebo vs Elagolix · mixed model repeated measures · p = < 0.001 (The P value is from MMRM with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -240.8
  • Placebo vs Elagolix + E2/NETA · mixed model repeated measures · p = < 0.001 (The P value is from MMRM with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -198.2
SecondaryPercentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6
Time frame:
Month 0 (Baseline), Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6
percentage of participantsPlaceboElagolixElagolix + E2/NETA
Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 616.165.961.5
Statistical analysis
  • Placebo vs Elagolix · chi-square or Fisher's exact test · p = < 0.001 (The P value is calculated based on chi-square test (or Fisher's exact test if ≥ 20% of the cells have expected cell count \< 5).) · Between-group difference (%): 49.7 · 95% CI 30.27 to 69.18
  • Placebo vs Elagolix + E2/NETA · chi-square or Fisher's exact test · p = < 0.001 (The P value is calculated based on chi-square test (or Fisher's exact test if ≥ 20% of the cells have expected cell count \< 5).) · Between-group difference (%): 45.4 · 95% CI 26.90 to 63.92
SecondaryChange From Baseline in MBL Volume to Month 1
Time frame:
Month 0 (Baseline), Month 1
Reported as:
Least squares mean · mL
Change From Baseline in MBL Volume to Month 1
mLPlaceboElagolixElagolix + Estradiol/Norethindrone Acetate
Change From Baseline in MBL Volume to Month 1-19.0 ± 16.05-209.0 ± 15.91-135.2 ± 11.41
Statistical analysis
  • Placebo vs Elagolix · mixed model repeated measures · p = < 0.001 (The P value is from MMRM with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -190.0
  • Placebo vs Elagolix + Estradiol/Norethindrone Acetate · mixed model repeated measures · p = < 0.001 (The P value is from MMRM with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -116.2

Adverse events

Collected over From first dose of study drug through 6 months of treatment with a 30-day follow-up period for participants who did not enroll in the extension study (Study M12-816). Mean (SD) treatment exposure was 158.6 (50.10), 161.2 (51.45), and 159.9 (53.48) days for the Placebo, Elagolix, and Elagolix and E2-NETA arms, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/102 (0%)5/102 (4.9%)29/102 (28.4%)
Elagolix0/104 (0%)3/104 (2.9%)81/104 (77.9%)
Elagolix + E2-NETA0/206 (0%)3/206 (1.5%)96/206 (46.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlaceboElagolixElagolix + E2-NETA
ANAEMIABlood and lymphatic system disorders2/1020/1040/206
UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1022/1040/206
OXYGEN SATURATION DECREASEDInvestigations1/1020/1040/206
OSTEOARTHRITISMusculoskeletal and connective tissue disorders1/1020/1040/206
SUICIDAL IDEATIONPsychiatric disorders1/1020/1040/206
MENORRHAGIAReproductive system and breast disorders1/1021/1040/206
DYSPNOEA EXERTIONALRespiratory, thoracic and mediastinal disorders1/1020/1040/206
PROLAPSEGeneral disorders0/1021/1040/206
ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions0/1021/1040/206
ECTOPIC PREGNANCYPregnancy, puerperium and perinatal conditions0/1021/1040/206
Most frequent other events
Most frequent other events
EventPlaceboElagolixElagolix + E2-NETA
HOT FLUSHVascular disorders9/10267/10442/206
NIGHT SWEATSSkin and subcutaneous tissue disorders3/10228/10414/206
HEADACHENervous system disorders9/10217/10417/206
NAUSEAGastrointestinal disorders10/1027/10423/206
FATIGUEGeneral disorders2/1021/10414/206
INSOMNIAPsychiatric disorders6/1027/1045/206
MOOD SWINGSPsychiatric disorders2/1027/1048/206
DYSMENORRHOEAReproductive system and breast disorders4/1021/10413/206
METRORRHAGIAReproductive system and breast disorders0/1021/10413/206
NASOPHARYNGITISInfections and infestations4/1026/10410/206

Baseline characteristics

All randomized and treated participants.

Age, Continuous
Age, Continuous(years)PlaceboElagolixElagolix + E2/NETATotal
Mean41.6 ± 5.6842.6 ± 5.1642.6 ± 5.3042.3 ± 5.37
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboElagolixElagolix + E2/NETATotal
Female102104206412
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboElagolixElagolix + E2/NETATotal
Hispanic or Latino1943457
Not Hispanic or Latino83100172355
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboElagolixElagolix + E2/NETATotal
American Indian or Alaska Native0022
Asian1236
Native Hawaiian or Other Pacific Islander0101
Black or African American7069141280
White302759116
More than one race1416
Unknown or Not Reported0101
08

Study locations

96 sites
  • Summers, Birmingham, AL /ID# 139684
    Birmingham, Alabama 35235, United States
  • University of South Alabama /ID# 148763
    Mobile, Alabama 36604-3302, United States
  • WCCT Global, LLC /ID# 145666
    Costa Mesa, California 92626, United States
  • American Clinical Trials /ID# 147374
    Hawaiian Gardens, California 90716, United States
  • Grossmont Ctr Clin Research /ID# 144011
    La Mesa, California 91942, United States
  • Long Beach Clinical Trial Serv /ID# 152424
    Long Beach, California 90806, United States
  • National Research Institute /ID# 151629
    Los Angeles, California 90057, United States
  • University of California, Los Angeles /ID# 144107
    Los Angeles, California 90095, United States
  • Beach OBGYN Medical Group /ID# 151414
    Newport Beach, California 92663-3657, United States
  • Advanced RX Clinical Research /ID# 149168
    Westminster, California 92683-4567, United States
  • Bluebird Clinical Trials, LLC /ID# 144843
    Colorado Springs, Colorado 80923, United States
  • Advanced Women's Health Institution /ID# 144108
    Greenwood Village, Colorado 80111, United States
  • Medstar Health Research Institute /ID# 145933
    Washington, District of Columbia 20010, United States
  • James A. Simon, MD, PC /ID# 139675
    Washington, District of Columbia 20036, United States
  • Helix Biomedics, LLC /ID# 147114
    Boynton Beach, Florida 33436-6634, United States
  • Brandon Premier Health Care, PA /ID# 153130
    Brandon, Florida 33510-3107, United States
  • Florida Clin Res Group /ID# 139811
    Ckearwater, Florida 33759, United States
  • Universal Clinical Research A /ID# 139742
    Doral, Florida 33166, United States
  • Clinical Physiology Associates /ID# 139736
    Fort Myers, Florida 33912, United States
  • Meridien Research /ID# 139663
    Kenneth City, Florida 33709-3113, United States
  • Altus Research, Inc /ID# 139662
    Lake Worth, Florida 33461, United States
  • South Florida Wellness & Clinic /ID# 143558
    Margate, Florida 33063, United States
  • LCC Medical Research Institute /ID# 143551
    Miami, Florida 33126, United States
  • Healthcare Clinical Data, Inc /ID# 139650
    Miami, Florida 33161, United States
  • Ocean Blue Med Research Ctr /ID# 139826
    Miami, Florida 33166, United States
  • Salom Tangir, LLC /ID# 151732
    Miramar, Florida 33027, United States
  • Advanced Research Institute /ID# 143554
    New Port Richey, Florida 34653, United States
  • Clinical Associates of Orlando /ID# 148123
    Orlando, Florida 32806, United States
  • Omega Research Consultants /ID# 139648
    Orlando, Florida 32810, United States
  • Unified Womens Clin Research /ID# 145169
    Panama City, Florida 32045, United States
  • Comprehensive Clinical Trials /ID# 139644
    West Palm Beach, Florida 33409, United States
  • Atlanta Medical Research Insti /ID# 147117
    Alpharetta, Georgia 30005-4419, United States
  • Paramount Research Solutions /ID# 139645
    Alpharetta, Georgia 30005, United States
  • Agile Clinical Research Trials /ID# 143563
    Atlanta, Georgia 30328, United States
  • Perimeter Inst Clinical Resear /ID# 148298
    Atlanta, Georgia 30338, United States
  • Masters of Clinical Research, Inc. /ID# 139658
    Augusta, Georgia 30909, United States
  • Fellows Research Alliance, Inc /ID# 139655
    Savannah, Georgia 31406, United States
  • Boise Family Medical Center /ID# 139844
    Boise, Idaho 83709, United States
  • Women's Health Practice, LLC /ID# 143569
    Champaign, Illinois 61820, United States
  • Great Lakes Clinical Trials /ID# 148135
    Chicago, Illinois 60640, United States
  • Affinity Clinical Research /ID# 150980
    Oak Brook, Illinois 60523, United States
  • American Health Network of IN /ID# 139822
    Avon, Indiana 46123, United States
  • GTC Research /ID# 141854
    Kansas City, Kansas 66218, United States
  • Cypress Medical Research Ctr /ID# 147116
    Wichita, Kansas 67226, United States
  • Research Integrity, LLC /ID# 139727
    Owensboro, Kentucky 42303-1089, United States
  • Clinical Trials Management, LLC - Covington /ID# 139651
    Covington, Louisiana 70433, United States
  • Ochsner Baptist Medical Center /ID# 139740
    New Orleans, Louisiana 70115, United States
  • Omni Fertility and Laser Insti /ID# 139836
    Shreveport, Louisiana 71118, United States
  • Capital Women's Care /ID# 144109
    Frederick, Maryland 21708, United States
  • Genesis Clinical Research - Fall River /ID# 148449
    Fall River, Massachusetts 02723, United States
  • Great Lakes Research Group,Inc /ID# 139659
    Bay City, Michigan 48706, United States
  • Grand Rapids Womens Health /ID# 139705
    Grand Rapids, Michigan 49503, United States
  • Wayne State University Physician Group - Southfield /ID# 139802
    Southfield, Michigan 48034, United States
  • Office of Edmond E. Pack, MD /ID# 139792
    Las Vegas, Nevada 89113, United States
  • Mabey, Las Vegas, NV /ID# 148138
    Las Vegas, Nevada 89128, United States
  • Lawrence OB/GYN /ID# 143567
    Lawrenceville, New Jersey 08648, United States
  • Bosque Women's Care /ID# 145934
    Albuquerque, New Mexico 87109, United States
  • Manhattan Medical Research /ID# 144471
    New York, New York 10016-6023, United States
  • Cwrwc /Id# 139664
    Durham, North Carolina 27713, United States
  • Unified Women's Clinical Research-Greensboro /ID# 139829
    Greensboro, North Carolina 27408, United States
  • Unified Women's Clinical Resea /ID# 139774
    Raleigh, North Carolina 27607, United States
  • PMG Research of Wilmington LLC /ID# 152563
    Wilmington, North Carolina 28401, United States
  • Unified Women's Clinical Resea /ID# 144721
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati /ID# 139820
    Cincinnati, Ohio 45267-0585, United States
  • Univ Hosp Cleveland /ID# 139741
    Cleveland, Ohio 44106, United States
  • Complete Healthcare for Women /ID# 139673
    Columbus, Ohio 43231, United States
  • Miami Valley Hospital /ID# 144430
    Dayton, Ohio 45409, United States
  • University of Toledo /ID# 139787
    Toledo, Ohio 43614, United States
  • Legacy Medical Group-Portland /ID# 148807
    Portland, Oregon 97210, United States
  • Main Line Fertility Center /ID# 150295
    Bryn Mawr, Pennsylvania 19010, United States
  • Penn State University and Milton S. Hershey Medical Center /ID# 139733
    Hershey, Pennsylvania 17033, United States
  • Thomas Jefferson University /ID# 139812
    Philadelphia, Pennsylvania 19107-4414, United States
  • Temple University Hospital /ID# 151429
    Philadelphia, Pennsylvania 19140, United States
  • Clinical Trials Research Svcs /ID# 139707
    Pittsburgh, Pennsylvania 15206, United States
  • Medical University of South Carolina /ID# 148754
    Charleston, South Carolina 29425, United States
  • Vista Clinical Research /ID# 139797
    Columbia, South Carolina 29201, United States
  • WR-ClinSearch /ID# 143538
    Chattanooga, Tennessee 37421-1605, United States
  • Research Memphis Associates, LLC /ID# 139674
    Memphis, Tennessee 38119-3895, United States
  • Access Clinical Trials, Inc. /ID# 139730
    Nashville, Tennessee 37203, United States
  • UT Southwestern Medical Center /ID# 143537
    Dallas, Texas 75390-7208, United States
  • Advances in Health, Inc. /ID# 139672
    Houston, Texas 77030, United States
  • Victorium Clinical Research /ID# 149630
    San Antonio, Texas 78230, United States
  • Discovery Clinical Trials-San Antonio /ID# 139776
    San Antonio, Texas 78258, United States
  • Houston Ctr for Clin Research /ID# 149149
    Sugar Land, Texas 77479, United States
  • Center of Reproductive Medicin /ID# 139813
    Webster, Texas 77598, United States
  • Eastern Virginia Med School /ID# 139647
    Norfolk, Virginia 23507-1627, United States
  • Clinical Research Partners, LL /ID# 143999
    North Chesterfield, Virginia 23235-4722, United States
  • Clinical Trials Virginia, Inc. /ID# 139801
    Richmond, Virginia 23225, United States
  • Emerson Clinical Research /ID# 147373
    Vienna, Virginia 22182, United States
  • Seattle Women's Health, Research, Gynecology /ID# 139768
    Seattle, Washington 98105, United States
  • Premier Clinical Research /ID# 148145
    Spokane, Washington 99202, United States
  • Froedtert and Medical College /ID# 143566
    Milwaukee, Wisconsin 53226-3522, United States
  • IWK Health Center /ID# 149066
    Halifax, Nova Scotia B3K 6R8, Canada
  • The Ottawa Hospital /ID# 148695
    Ottawa, Ontario K1H 8L6, Canada
  • Rodriguez-Ginorio, San Juan /ID# 139847
    San Juan, 00917, Puerto Rico
  • School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 139848
    San Juan, 00935, Puerto Rico
09

References and documents

Publications

  • Beck D, Winzenborg I, Liu M, Degner J, Mostafa NM, Noertersheuser P, Shebley M. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. Clin Pharmacokinet. 2022 Apr;61(4):577-587. doi: 10.1007/s40262-021-01096-w. Epub 2021 Dec 8. PubMed 34878624 ↗
  • Stewart EA, Archer DF, Owens CD, Barnhart KT, Bradley LD, Feinberg EC, Gillispie-Bell V, Imudia AN, Liu R, Kim JH, Al-Hendy A. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 May;31(5):698-705. doi: 10.1089/jwh.2021.0152. Epub 2021 Sep 28. PubMed 34582715 ↗
  • Muneyyirci-Delale O, Archer DF, Owens CD, Barnhart KT, Bradley LD, Feinberg E, Gillispie V, Hurtado S, Kim JH, Wang A, Wang H, Stewart EA. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis. F S Rep. 2021 May 26;2(3):338-346. doi: 10.1016/j.xfre.2021.05.004. eCollection 2021 Sep. PubMed 34553161 ↗
  • Beck D, Winzenborg I, Gao W, Mostafa NM, Noertersheuser P, Chiuve SE, Owens C, Shebley M. Integrating real-world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women. Clin Transl Sci. 2021 Jul;14(4):1452-1463. doi: 10.1111/cts.13006. Epub 2021 Apr 8. Erratum In: Clin Transl Sci. 2022 Mar;15(3):799. doi: 10.1111/cts.13188. PubMed 33650259 ↗
  • Al-Hendy A, Bradley L, Owens CD, Wang H, Barnhart KT, Feinberg E, Schlaff WD, Puscheck EE, Wang A, Gillispie V, Hurtado S, Muneyyirci-Delale O, Archer DF, Carr BR, Simon JA, Stewart EA. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2021 Jan;224(1):72.e1-72.e50. doi: 10.1016/j.ajog.2020.07.032. Epub 2020 Jul 20. PubMed 32702363 ↗
  • Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, Feinberg EC, Hurtado SM, Kim J, Liu R, Mabey RG Jr, Owens CD, Poindexter A, Puscheck EE, Rodriguez-Ginorio H, Simon JA, Soliman AM, Stewart EA, Watts NB, Muneyyirci-Delale O. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 Jan 23;382(4):328-340. doi: 10.1056/NEJMoa1904351. PubMed 31971678 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Jan 2018, 24 months.

Results were first posted in Jun 2020, 2 years 5 months after primary completion. A results delay was requested in Dec 2018.

Of 25 phase 3 interventional studies under Leiomyoma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 41. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2016
First posted
Jan 13, 2016
StartActual
Dec 22, 2015
Primary completionActual
Jan 18, 2018
CompletionActual
Dec 12, 2018
Results delay requested
Dec 3, 2018
Results first posted
Jun 29, 2020
Last update
Jun 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02654054
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 13, 2016
Start date
Dec 22, 2015
Primary completion
Jan 18, 2018
Completion
Dec 12, 2018
Results posted
Jun 29, 2020
Last update
Jun 29, 2020

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elagolix · Estradiol · Norethindrone Acetate

Start the discussion